Header Logo

Connection

ROBERT ATMAR to Antibodies, Neutralizing

Back to Details
This is a "connection" page, showing publications ROBERT ATMAR has written about Antibodies, Neutralizing.
ROBERT ATMAR
Connection Strength
3.584
Antibodies, Neutralizing
  1. Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen-Blocking Antibody Levels. J Infect Dis. 2024 Dec 16; 230(6):1376-1379.
    View in: PubMed
    Score: 0.717
  2. A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies. J Infect Dis. 2024 May 15; 229(5):1402-1407.
    View in: PubMed
    Score: 0.689
  3. Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022 03 17; 386(11):1046-1057.
    View in: PubMed
    Score: 0.587
  4. Comparison of Microneutralization and Histo-Blood Group Antigen-Blocking Assays for Functional Norovirus Antibody Detection. J Infect Dis. 2020 02 18; 221(5):739-743.
    View in: PubMed
    Score: 0.513
  5. Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity. Clin Vaccine Immunol. 2015 Feb; 22(2):221-8.
    View in: PubMed
    Score: 0.359
  6. Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clin Infect Dis. 2025 02 05; 80(1):223-227.
    View in: PubMed
    Score: 0.181
  7. Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost. Nat Commun. 2025 Jan 17; 16(1):759.
    View in: PubMed
    Score: 0.180
  8. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-na?ve subjects. Vaccine. 2015 Sep 22; 33(39):5225-34.
    View in: PubMed
    Score: 0.093
  9. Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59?. Vaccine. 2025 Feb 15; 47:126702.
    View in: PubMed
    Score: 0.045
  10. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 06 14; 78(6):1757-1768.
    View in: PubMed
    Score: 0.043
  11. Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial. Clin Infect Dis. 2023 08 22; 77(4):560-564.
    View in: PubMed
    Score: 0.041
  12. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep Med. 2022 07 19; 3(7):100679.
    View in: PubMed
    Score: 0.038
  13. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019 05 01; 37(19):2561-2568.
    View in: PubMed
    Score: 0.030
  14. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Vaccine. 2017 03 23; 35(13):1675-1682.
    View in: PubMed
    Score: 0.026
  15. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. J Infect Dis. 2014 Dec 01; 210(11):1763-71.
    View in: PubMed
    Score: 0.022
  16. Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 01; 206(7):1069-77.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.